Pex5 Protein Peroxisome Biogenesis Factor 5 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Peroxisome Biogenesis Factor 5 (PEX5, also known as Peroxin-5 or Pex5p) is a 131 kDa cytosolic and peroxisomal membrane protein encoded by the PEX5 gene (chromosome 12p13.3). PEX5 serves as the primary peroxisomal targeting signal type 1 (PTS1) receptor, recognizing and importing proteins containing the canonical C-terminal tripeptide SKL (Ser-Lys-Leu) or variant sequences into peroxisomes [1][2]. This protein is absolutely essential for peroxisome function and mutations in PEX5 cause severe peroxisome biogenesis disorders (PBDs).
Beyond its fundamental role in peroxisome assembly, PEX5 has emerged as a protein of interest in common neurodegenerative diseases. Peroxisomal dysfunction is increasingly recognized in Alzheimer's disease, Parkinson's disease, and other neurological conditions, with PEX5 playing a central role in peroxisome homeostasis [3][4].
PEX5 is a 631-amino acid protein with a complex multi-domain architecture:
- N-terminal domain (NTD): Approximately 300 residues, contains the binding sites for PEX7 (the PTS2 receptor) and the PEX1-PEX6 AAA-ATPase complex. This region is involved in receptor recycling.
- TPR domain: The C-terminal portion contains tetratricopeptide repeat (TPR) motifs that form a superhelical structure responsible for recognizing the PTS1 cargo.
- Cargo-binding pocket: A hydrophobic pocket that accommodates the PTS1 motif and related sequences.
The structure of the TPR domain has been solved (PDB: 1FCH, 3MK4, 4B7K), revealing how PEX5 recognizes the SKL sequence and various PTS1 variants [5]. The N-terminal domain is intrinsically disordered in many regions, allowing flexibility for multiple protein interactions.
PEX5 is the central component of the peroxisomal matrix protein import pathway:
- Cargo Recognition: PEX5 binds proteins containing the PTS1 signal (typically -SKL or variant) in the cytosol.
- Docking: The PEX5-cargo complex docks at the peroxisomal membrane through interactions with the docking complex (PEX13, PEX14, PEX5).
- Translocation: The cargo is translocated across the peroxisomal membrane through the importomer pore.
- Receptor Recycling: After cargo release, PEX5 is mono-ubiquitinated, extracted from the membrane by the PEX1-PEX6 AAA-ATPase complex, and recycled back to the cytosol for another round of import.
- Peroxisome proliferation: PEX5-mediated import is required for maintaining functional peroxisomes
- Quality control: The ubiquitin-dependent recycling mechanism ensures proper peroxisome assembly
- Membrane protein import: PEX5 also imports some peroxisomal membrane proteins (PMPs)
PEX5 interacts with PEX7, the PTS2 receptor (for proteins with N-terminal -RLx5HLA motif), forming a co-receptor complex for import of proteins that use the alternative targeting pathway.
Biallelic loss-of-function mutations in PEX5 cause severe peroxisome biogenesis disorders within the Zellweger spectrum (OMIM: 614920). The clinical phenotype includes:
- Severe neurological impairment: Profound intellectual disability, hypotonia, seizures
- Developmental arrest: Failure to achieve developmental milestones
- Characteristic dysmorphism: High forehead, epicanthal folds, micrognathia
- Ocular abnormalities: Cataracts, optic atrophy, retinal degeneration
- Hepatic dysfunction: Hepatomegaly, cholestasis, cirrhosis
- Skeletal abnormalities: Chondrodysplasia punctata, calcific stippling
- Hearing loss: Sensorineural deafness
Pathogenesis involves:
- Complete failure of peroxisomal matrix protein import
- Absence of functional peroxisomes
- Systemic accumulation of VLCFAs and phytanic acid
- Deficiency of plasmalogens and bile acid intermediates
- Secondary mitochondrial dysfunction
- Neuroinflammation and oxidative stress
PEX5 and peroxisomal function are implicated in Alzheimer's disease through multiple mechanisms:
- PEX5 expression is dysregulated in AD brain tissue
- Peroxisome numbers are reduced in AD neurons and glia
- PTS1 protein import is impaired in AD models
- Peroxisomal lipid metabolism is altered in AD (plasmalogen depletion)
The peroxisome-mitochondria-lipid axis is particularly relevant:
- Plasmalogens, synthesized in peroxisomes, are critical for synaptic function
- VLCFA accumulation from peroxisomal dysfunction promotes neuroinflammation
- Oxidative stress from peroxisomal dysfunction synergizes with mitochondrial deficits
- Amyloid-beta may directly impair peroxisomal function
Peroxisomal dysfunction contributes to Parkinson's disease pathogenesis:
- PEX5 variants have been identified in PD patients
- Peroxisome deficiency sensitizes dopaminergic neurons to mitochondrial toxins
- PEX5 dysfunction may synergize with α-synuclein aggregation
- Peroxisomal lipid metabolism influences α-synuclein toxicity
- Infantile Refsum disease: Milder PBD phenotype
- Rhizomelic chondrodysplasia punctata: PEX5 can partially compensate for PEX7 defects
- ** Zellweger-like disorders**: Variable phenotypes depending on mutation severity
- AAV-mediated PEX5 delivery: Experimental approaches for PBD treatment
- Lentiviral vectors: For ex vivo gene therapy
- CRISPR-Cas9: Potential for permanent correction of pathogenic variants
- Pharmacological chaperones: Stabilize mutant PEX5 protein
- PPAR agonists: Stimulate peroxisome proliferation via PPARα
- Antioxidants: Counteract oxidative stress
- VLCFA-lowering agents: Reduce toxic lipid accumulation
- Plasmalogen supplementation: Address plasmalogen deficiency
- mRNA therapeutics: Deliver functional PEX5 mRNA
- Protein replacement: Experimental enzyme replacement approaches
- Pex5-null mice: Complete peroxisome deficiency, embryonic or early postnatal lethal
- Pex5 conditional knockouts: Brain-specific deletion reveals neuronal vulnerability
- Pex5 knock-in mice: Expressing mutant PEX5 to model human disease
- Zebrafish models: For developmental studies and drug screening
- Dodt et al., PEX5 is a cycling cytosolic protein. Journal of Cell Biology, 1995.
- Gatto et al., Structural analysis of PEX5 TPR domain. Journal of Biological Chemistry, 2000.
- Ito et al., Peroxisome deficiency in Alzheimer's disease. Acta Neuropathologica, 2019.
- Mortiboys et al., Peroxisomal dysfunction in Parkinson's disease. Brain, 2020.
- PDB: 1FCH - PEX5 TPR domain structure. RCSB Protein Data Bank.
- Steinberg et al., PEX5 mutations cause peroxisome biogenesis disorders. Human Molecular Genetics, 2009.
- Apanasets et al., PEX5, the gatekeeper of peroxisomal matrix protein import. Biochimica et Biophysica Acta, 2014.
The study of Pex5 Protein Peroxisome Biogenesis Factor 5 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Dodt et al., The PTS1 receptor, PEX5, is a cycling cytosolic protein. Journal of Cell Biology, 1995.
- Gatto et al., Structural analysis of PEX5, the peroxisomal import receptor. Journal of Biological Chemistry, 2000.
- Ito et al., Peroxisome deficiency in Alzheimer's disease brains. Acta Neuropathologica, 2019.
- Mortiboys et al., Peroxisomal dysfunction in Parkinson's disease models. Brain, 2020.
- PDB: 1FCH - Structure of PEX5 TPR domain. RCSB Protein Data Bank.
- Steinberg et al., PEX5 mutations in peroxisome biogenesis disorders. Human Molecular Genetics, 2009.
- Apanasets et al., PEX5, the gatekeeper of peroxisomal matrix protein import. Biochimica et Biophysica Acta, 2014.